Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients.

Author: Yi Lin CHEN ¹ ; Li MENG ² ; Guo Lin YUAN ³ ; Zhuang Zhi YANG ⁴ ; Zhi Ping HUANG ⁵ ; You Shan ZHANG ⁶ ; Zhe ZHAO ⁷ ; Chu Cheng WANG ⁸ ; Ying BAO ⁹ ; Hang XIANG ¹⁰ ; Hua YIN ¹ ; Li Feng CHEN ¹ ; Ying Yuan XIONG ¹ ; Long WANG ¹¹ ; Wei Ming LI ¹
Author Information

1. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
2. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
3. Xiangyang Central Hospital, Xiangyang 441021, China.
4. Suizhou Central Hospital, Suizhou 441300, China.
5. Jingzhou Central Hospital, Jingzhou 434020, China.
6. The First People's Hospital of Jingzhou, Jingzhou 434000, China.
7. MinDa Hospital Affiliated to Hubi Institute for Nationalities, Enshi 445000, China.
8. Shiyan Taihe Hospital, Shiyan 442000, China.
9. The First People's Hospital of Xiangyang, Xiangyang 441000, China.
10. Central Hospital of Enshi Autonomous Prefecture, Enshi 445000, China.
11. The First People's Hospital of Jingmen, Jingmen 448000, China.
Publication Type:Journal Article
MeSH: Antineoplastic Agents/therapeutic use*; Dasatinib/therapeutic use*; Humans; Leukemia, Myeloid, Chronic-Phase/drug therapy*; Prognosis; Protein Kinase Inhibitors; Treatment Outcome
From: Chinese Journal of Hematology 2019;40(7):608-611
CountryChina
Language:Chinese